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ABSTRACT 
The research involves characterization of in vitro and in vivo activity of mucoadhesive microspheres for Helicobacter pylori 
eradication. Amoxicillin and Famotidine were used as model drugs so that the dual therapy gives better H. pylori eradication. 
Preparation was carried by an emulsion-solvent evaporation method and 27 batches were prepared individually using 33 factorial 
designs to study the effect of independent variables on dependent variables. The in vitro mucoadhesion test and in vivo studies 
(Bacterial clearance study, in vivo mucoadhesion and in vivo ulcer index studies) were performed. A27 batch showed 66% 
mucoadhesion after 10 h and F24 showed 74% of mucoadhesion after 10 h. In the bacterial clearance studies, the mean bacterial 
count (log colony forming units) after oral administration of drug-loaded microspheres was found to be 3.72 ± 0.58. The drug-loaded 
microspheres formulation exhibited better clearance from infection than plain drugs solution at the same doses. Drug microspheres 
formulation was found to be effective in the treatment of H. pylori infections effectively, and in in vivo mucoadhesion studies, the 
developed system was well taken up and processed by the cells of gastric mucosa of the stomach. 
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INTRODUCTION:  
More than 50% of drug delivery systems available in the 
market are oral drug delivery systems. These systems 
have the obvious advantages of ease of administration 
and patient acceptance. Attempts to develop a single-
dose therapy for the whole duration of treatment have 
focused attention on controlled or sustained release drug 
delivery systems. Gastro retention helps provide a better 
availability of new products with new therapeutic 
possibilities and substantial benefits for patients. GRDFs 
greatly improve the pharmacotherapy of the stomach 
through local drug release drug concentrations at the 
gastric mucosa (eradicating H. pylori from the sub 
mucosal tissue of the stomach), making it possible to 
treat stomach and duodenal ulcers, gastritis, and 
esophagitis. This can be achieved by coupling 
bioadhesion characteristics to microspheres and 
developing characteristics to microspheres and 
developing mucoadhesive microspheres 
1
. H. pylori is a 
major gastric pathogen in the worldwide distribution; 
these are spiral-shaped bacteria found in the stomach, 
which destroy stomach along with the duodenal tissue, 
Several treatment regimens are emerging for H. pylori 
infection from the early 1990s, when monotherapy was 
first recommended. Even though H. pylori is highly 
sensitive to most of the antibiotics, its elimination is not 
easy even with the best currently available therapy
2
. 
Therapeutic regimens directed against H. pylori 
infection will continue to evolve. Amoxicillin (-amino-
hydroxybenzylpenicillin) is a semi-synthetic, orally 
absorbed, broad-spectrum antibiotic. It is now widely 
used in the standard eradication treatment of gastric and 
duodenal ulcers 
3
. Famotidine is a histamine H2-receptor 
antagonist. It is mostly prescribed for gastric ulcers, 
duodenal ulcers, also for gastro esophageal reflux 
diseases. With low bioavailability (40-45%) and short 
biological half-life (2.5-4.0 h), it favors the development 
of a sustained release formulation 
4
. Thus, an attempt 
was made in the present investigation to prepare 
mucoadhesive microspheres. The microspheres were 
characterized by in vitro and in vivo tests and factorial 
design was used to optimize the variables. 
METHODS: 
The mucoadhesive microspheres were prepared by 
emulsion solvent evaporation method using Carbopol 
934 and ethyl cellulose as polymers. In the first step, 
ethyl cellulose was dissolved in 200 ml of ethanol and 
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then drug and polymer were dispersed in the solution of 
ethyl cellulose under stirring. The preliminary trial 
batches were prepared and optimized using 3
3
 factorial 
design earlier by varying the drug-to-polymer-to-
polymer (amoxicillin/famotidine-ethyl cellulose-
carbopol-934P) ratio in the range of 1:3:1% to 1:3:3%. 
The final mixture was extruded through a syringe (gauge 
No. 20) in 500 ml of liquid paraffin (mixture of heavy 
and light, 1:1 ratio) containing Span 80 and stirring was 
carried out using a propeller stirrer (Remi, Mumbai, 
India) at 1000 rpm. The stirring was done for 3 h. In 
preliminary trial batches, the amount of emulsifying 
agent (1-3%), the drug: polymer concentration 1:3:1% to 
1:3:3%, and stirring speed (500-1000 rpm) were varied 
RESULTS AND DISCUSSION:  
Optimization of amoxicillin-loaded microspheres  
For preparation, a full factorial design was employed. A 
design model with 3 factors, 3 levels, and 27 runs was 
selected for the optimization study. The dependent 
variables obtained at various levels of the 3 independent 
variables (X1, X2, and X3) were subjected to multiple 
regression to yield a second-order polynomial equation 
obtained coefficient. The polynomial equation generated 
by this experimental design (using Design Expert 7.1.6) 
was as follows:  
Y= b0 +b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 
+ b23X2X3 + b11X1X1 + b22X2X2 + b33X3 
Where, Y is the dependent variable; b0 is the intercept; 
b1 to b33 are the regression coefficients; and X1, X2, 
and X3 are the independent variables. Response surface 
graphs for amoxicillin are shown in Figures 1-4 and for 
famotidine are shown in Figures 5-8.  
In vitro Mucoadhesion  
The in vitro mucoadhesiveness test was carried out 
among the factorial design batches based on good 
entrapment efficiency and the batch A27 and F24 
showed that even after 10 h, 66% and 74% microspheres 
were adhered to the gastric mucous layer. The 
mucoadhesive microspheres were spherical and free 
flowing.
 
 
 
 
Figure 1: Contour plot for drug entrapment Figure 2: Contour plot for particle size 
 
 
Figure 3: Response surface plot for drug entrapment     Figure 4: Response surface plot for particle size 
 
 
Figure 5: Contour plot for drug entrapment                   Figure 6: contour plot for particle size 
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Figure 7: Response surface plot for drug entrapment          Figure 8: Response surface plot for particle size 
 
In vitro drug release studies  
A sustained drug release was obtained for more than 10h. 
 
Figure 9: Dissolution profile 
In vivo studies  
Bacterial clearance count  
Infected animal model, i.e, male albino rats with H. 
pylori was used for in vivo study. The control group of 
rat received only physiological saline. The mean 
bacterial count (log CFU) was found to be 9.64 ± 0.35. 
The mean bacterial count (log CFU) after oral 
administration of plain drugs solution (amoxicillin) was 
found to be 5.83 ± 0.23, which is due to unavailability of 
100% drugs and short residence. The mean bacterial 
count (log CFU) after oral administration of drug-loaded 
microspheres was found to be 3.72 ± 0.58.  
In vivo mucoadhesion study  
The mucoadhesive behavior of the microspheres was 
determined after 2 h of incubation of films pieces in the 
stomach and intestine. This muco-adhesivity was also 
confirmed in vivo using FITC dye with the formulation. 
This shows that the system could attach the mucosal gel 
layer where H. pylori resides [Figures 10 and 11].  
 
        
Figure 10: Plain fluorescence  
isothiocyanate solution   
Figure11: Fluorescence isothiocyanate-labeled                           
microspheres in gastric tissue (after 2 h) 
                                                           
In vivo ulcer index studies  
 
Figure 12: (a) Ulcer-induced rat stomach. (b) 
Famotidine suspension-treated. (c) Mucoadhesive 
microsphere-treated 
Mucoadhesive microsphere dispersion showed a 
significant decrease in ulcer index (0.46 ± 0.011) when 
compared with the control group (3.61 ± 0.14) and 
famotidine suspension-treated animal (0.66 ± 0.035) 
(Figure 12). 
CONCLUSION: 
The mucoadhesive microspheres were developed using a 
3
3
 factorial design and showed a high percentage of 
mucoadhesion, drug entrapment efficiency, and 
exhibited a sustained release property. The formulation 
showed more effective H. pylori activity of  
mucoadhesive amoxicillin microspheres compared to 
amoxicillin and famotidine mucoadhesive microsphere 
dispersion showed a significant decrease in ulcer index 
when compared with the control group and famotidine 
suspension-treated animal, which might indicate a 
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potential use of mucoadhesive microspheres in treating H. pylori infection. 
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